5 alpha-reductase inhibitors associated changes in prostate zonal shape. 

<h2 id="background">Background</h2><ul><li>Benign prostatic hyperplasia (BPH) is a common issue in elderly men, characterized by increased prostate blood vessel growth leading to worsened urinary symptoms and reduced quality of life. Dutasteride, a 5a-reductase inhibitor, is a key treatment option for BPH due to its ability to shrink the prostate.</li></ul><h2 id="aim">Aim</h2><ul><li>To analyze alterations in the shapes of prostate zones resulting from dutasteride treatment of BPH, using MRI.</li></ul><h2 id="methods">Methods</h2><ul><li>Study examined 19 drug-administered patients and 33 non-drug-administered patients.</li><li>MRI sections of all participants before and after drug treatment were collected retrospectively.&nbsp;</li><li>The transition zone and peripheral zone of the prostate were marked with selected landmarks using TPSDIG v2.04.</li><li>Generalized Procrustes Analysis was used to analyze shapes statistically.</li></ul><h2 id="results">Results</h2><ul><li>There was a significant difference in the initial prostate shapes (p = 0.003) (Fig 1) and final<br>shapes (p = 0.007) (Fig 2) revealed by landmark markings on TZ sections between the patient groups who used and did not use the medication.</li></ul><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/urology-fig1.webp" width="993" height="484"></p><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/urology-fig2.webp" width="982" height="415"></p><ul><li>This difference was caused by greater enlargement at the posterior part and greater narrowing at the anterior part of the TZ in the drug-using group than in the non-drug-using group (Fig 3).</li></ul><p style="text-align:center;"><img src="https://cdn.megawecare.com/GHBY/Internal-Images/urology-fig3.webp" width="1006" height="439"></p><h2 id="conclusion">Conclusion</h2><ul><li>Study results show, use of 5a-reductase inhibitors yielded favorable outcomes in terms of prostate size reduction and improved symptoms associated with BPH.</li></ul>

<ul><li><a href="#background">Background</a></li><li><a href="#aim">Aim</a></li><li><a href="#methods">Methods</a></li><li><a href="#results">Results</a></li><li><a href="#conclusion">Conclusion</a></li></ul>

5 alpha-reductase inhibitors associated changes in prostate zonal shape.

Reference